Details for Patent: 12,274,793
Which drugs does patent 12,274,793 protect, and when does it expire?
Patent 12,274,793 protects CREXONT and is included in one NDA.
This patent has thirty patent family members in fourteen countries.
Summary for Patent: 12,274,793
| Title: | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof |
| Abstract: | The invention provides an oral solid formulation comprising (a) one or more controlled release components comprising a core comprising levodopa, esters or salts thereof and wherein the one or more controlled release components; and (b) one or more immediate release components comprising levodopa, esters or salts thereof. The oral solid formulation also contains a decarboxylase inhibitor and about 80% to 100% of the decarboxylase inhibitor present in the oral solid formulation is present in the one or more immediate release components. |
| Inventor(s): | Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta |
| Assignee: | Impax Laboratories LLC |
| Application Number: | US18/911,732 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,274,793 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; Dosage form; |
Drugs Protected by US Patent 12,274,793
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-001 | Aug 7, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-002 | Aug 7, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-003 | Aug 7, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Impax | CREXONT | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 217186-004 | Aug 7, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,274,793
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014332024 | ⤷ Start Trial | |||
| Australia | 2019284060 | ⤷ Start Trial | |||
| Australia | 2021282393 | ⤷ Start Trial | |||
| Canada | 2926082 | ⤷ Start Trial | |||
| China | 105658211 | ⤷ Start Trial | |||
| Denmark | 3782614 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
